AGROAMERICA
5.9.2020 03:28:08 CEST | Business Wire | Press release
AgroAmerica, a globally recognized sustainable company, has been invited since 2017 to sponsor the Central American Donors Forum , an initiative of the Seattle International Foundation (SIF), to generate alliances and advance in development efforts in Central America to generate a greater social impact.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200904005525/en/
The Forum has the participation of over 400 leaders from business, government, private sector, media outlets, and civil society, as well as international and regional panelists, to discuss priority issues and promote Social Responsibility. For the first time since its inception, the 2020 Forum was held virtually and was open to all audiences.
From September 1 - 3, 2020, the interventions of the different Forum participants focused on the “Reinvention and resistance in times of crisis” . The COVID-19 pandemic has exposed many of the vulnerabilities and concerns of Central America based on the construction of alternative responses to the economic impact, gender approach, migration, and the role of companies to increase market access for all.
Promoting development:
For the 4th consecutive year, AgroAmerica participated as a sponsor of the Forum, promoting the development of the Central American region and the implementation of good business, labor, social and environmental practices.
During 2019, the Forum's central theme was “Progress at the Crossroads”. More than 30 conferences, panels, and workshops were held in Tegucigalpa, Honduras, addressing Economic Development, Youth, Feminist Movements, Corruption, Migration, Human Rights, Democracy, Public-Private Partnerships, among others.
In 2018, the forum was held in San Salvador, El Salvador, developing the theme “Creating space for everyone”, highlighting the role of corporate social responsibility in building a more inclusive region through strategic alliances with social actors.
In 2017, AgroAmerica CEO, Fernando Bolaños, was a member of the host committee, as well as a panelist of the Forum that revolved around the theme “Reimagining Partnerships” held in Panama City.
Bolaños participated on the panel Social Responsibility: The Role of Influential People in the Construction of Democracy in Central America . “There are many challenges facing Central America,” said Bolaños during his intervention. “Our challenges are all connected and linked – food security, poverty, gender equality, health and education to name just a few. At AgroAmerica we strive to create a sustainable development initiative through partnerships, so we can improve the lives of our employees and the people in the surrounding communities.”
AgroAmerica will continue contributing to initiatives that promote a more inclusive region through its Corporate Sustainability Strategy and strategic alliances with social actors.
About AgroAmerica:
AgroAmerica is an agroindustrial corporation dedicated the production and commercialization of food products, using sustainable and responsible farming methods. With operations in Europe, United States, México, Guatemala, Ecuador, Perú, and Panamá. AgroAmerica operates based on a Corporate Sustainability strategy to generate value and balance among economic growth, natural resource conservation, and our customers and stakeholders wellbeing. Visit us: https://agroamerica.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200904005525/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release
Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
